190 related articles for article (PubMed ID: 28743508)
21. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X
Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330
[TBL] [Abstract][Full Text] [Related]
22. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X
Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537
[TBL] [Abstract][Full Text] [Related]
23. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
24. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
25. Recent research advances in ATX inhibitors: An overview of primary literature.
Zhang C; Liu Y; Zhou Q; Fan H; Liu X; Hu J
Bioorg Med Chem; 2023 Jul; 90():117374. PubMed ID: 37354726
[TBL] [Abstract][Full Text] [Related]
26. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
[TBL] [Abstract][Full Text] [Related]
27. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
28. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405
[TBL] [Abstract][Full Text] [Related]
29. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
30. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
31. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.
Fells JI; Lee SC; Norman DD; Tsukahara R; Kirby JR; Nelson S; Seibel W; Papoian R; Patil R; Miller DD; Parrill AL; Pham TC; Baker DL; Bittman R; Tigyi G
FEBS J; 2014 Feb; 281(4):1017-28. PubMed ID: 24314137
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of picolinamides and thiazole-2-carboxamides as mGluR5 (metabotropic glutamate receptor 5) antagonists.
Vu HN; Kim JY; Hassan AH; Choi K; Park JH; Park KD; Lee JK; Pae AN; Choo H; Min SJ; Cho YS
Bioorg Med Chem Lett; 2016 Jan; 26(1):140-4. PubMed ID: 26598462
[TBL] [Abstract][Full Text] [Related]
34. "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.
Stylianaki EA; Magkrioti C; Ladopoulou EM; Papavasileiou KD; Lagarias P; Melagraki G; Samiotaki M; Panayotou G; Dedos SG; Afantitis A; Aidinis V; Matralis AN
Eur J Med Chem; 2023 Mar; 249():115130. PubMed ID: 36702053
[TBL] [Abstract][Full Text] [Related]
35. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
36. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
[TBL] [Abstract][Full Text] [Related]
37. Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors.
Jia F; Lei H; Chen Y; Li T; Xing L; Cao Z; Zhai X
Bioorg Med Chem; 2020 Nov; 28(22):115795. PubMed ID: 33032188
[TBL] [Abstract][Full Text] [Related]
38. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors.
Ma S; Wang L; Ouyang B; Fan M; Qi J; Yao L
Bioorg Med Chem; 2020 Oct; 28(19):115683. PubMed ID: 32912437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
